Regulating CRISPR: FDA and Industry Offer Perspective – Regulatory Focus
Regulatory Focus |
Regulating CRISPR: FDA and Industry Offer Perspective
Regulatory Focus Although the US market is likely more than a year or two away from seeing any commercialized medical products that rely on CRISPR-Cas9 technology, the rapidly developing field has already grabbed the attention of the US Food and Drug Administration … Crispr Therapeutics AG (CRSP) CEO Sells $54823.00 in Stock |
